⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 5, 2024Journal of the National Comprehensive Cancer Network

HSR24-142: Real-World Clinical Benefit Among Patients (pts) With Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated With Luspatercept

Kashyap Patel B. Plazas Snyder Derek Tang Debanjana Chatterjee Anupama Vasudevan Uchechukwu Mordi Harvey Katzen John Li Lindsay Aton Ali McBride

View at Publisher

Ask AI

Bookmark

Share

Abstract

"HSR24-142: Real-World Clinical Benefit Among Patients (pts) With Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated With Luspatercept" published on 05 Apr 2024 by National Comprehensive Cancer Network.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Patel et al. (2024) studied this question.

synapsesocial.com/papers/68e70542b6db64358767ebb9 https://doi.org/10.6004/jnccn.2023.7143

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1HSR24-133: Real-World (RW) Effectiveness of Erythropoiesis-Stimulating Agents (ESAs) After Luspatercept in Patients (pts) With Myelodysplastic Syndromes (MDS): A Retrospective Analysis of a Large Healthcare Claims Database in the United States2024
2Luspatercept for the treatment of myelodysplastic syndrome: A retrospective cohort study utilizing trinetx2025
3Luspatercept for Patients with Lower-Risk Myelodysplastic Syndromes/Neoplasms: A Systematic Review and Meta-Analysis2025 · 6 citations
4The efficacy and safety of luspatercept in patients with low-blasts myelodysplastic neoplasms in real world2025
5Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)–naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial.2024 · 2 citations

More related papers

Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world clinical practice: exploring the positive effect of combination with erythropoietin alfa2024
Interest of luspatercept in treatment of anemia in lower-risk of myelodysplastic syndrome anemia: a single center study of 26 patients2026
Clinical benefit of luspatercept in erythropoiesis-stimulating agent (ESA)-naive patients (pts) with early disease characteristics and very low-, low-, or intermediate-risk Myelodysplastic Syndromes (LR-MDS): A post hoc analysis from the commands trial2025

More from Journal of the National Comprehensive Cancer Network

Care Outcomes Among Hospitalized Patients With Cancer: A Retrospective Cohort StudyTue,
Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation: A Multicenter Retrospective StudyTue,